Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: Results from a retrospective cohort study

Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy

“…The dose-response relationship found between recency of IVIg exposure and arterial TEE risk is consistent with the temporal pattern reported in case reports and case series. 9,10,30 This finding is also consistent with the approximately 30-day half-life of exogenous IgG 47,48 and hypothesized transient effect of IVIg on TEE risk. In contrast to the primary arterial TEE endpoint, we did not find a clear temporal relationship between recency of IVIg exposure and the venous TEE secondary end point.…”

“…In a previous observational study that reported on TEEs that occurred within 30 days of IVIg treatment, the median time from IVIg treatment until onset of symptomatic TEE was 1 day for arterial events vs 10 days for venous events. 30 In addition, IVIg users were more likely than matched nonusers to be hospitalized for pneumonia (15% vs 12%) over the 1-year follow-up period; this suggests that the excess venous TEE risk observed among the IVIg users may be partially attributable to confounding by immobility, a strong risk factor for venous TEEs.…”

“…13,14,[24][25][26][27][28][29][30][31][32] However, the extent to which these events are attributable to the IVIg itself rather than other risk factors is unclear, as is the risk associated with low doses of IVIg for immunodeficiency. In this retrospective cohort study, we assessed rates of clinically serious arterial and venous TEEs in older patients with CLL or MM who initiated IVIg therapy.…”

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

“…1,41,47,59,116,144,146,148,151-153,155,156 It is worth noting that the presence of adverse events varies between different products, or even between different batches of the same product. Some patients have adverse effects with one or more Ig products, but not all of them.…”

Prophylactic anticoagulation in Guillain-Barré syndrome: too much of a good thing?: Table 1

“…2 Prolonged flaccid limb weakness and the use of intravenous immunoglobulin are risk factors for the development of VTE in patients with GBS. 3 While consensus statements regarding VTE prophylaxis in those with GBS do exist, these are often based on evidence from studies involving postoperative patients and as such do not specifically address the risk-benefit profile of various VTE prophylaxis regimens in GBS. 4 At a recent mortality review meeting at our institution, we discussed the case of a 45-year-old patient with GBS in the intensive treatment unit (ITU) who died as a result of bleeding from his tracheostomy.…”